Biocept Announces Clinical Validation and Commercial Launch of its Target Selector™ Multi-Gene Liquid Biopsy Panel for Lung Cancer
Lung cancer is the leading cause of cancer death for both men and women in
"We are very pleased to launch our first multi-gene liquid biopsy panel to physicians and researchers in both academic centers and the pharmaceutical industry," said
About
About
Forward-Looking Statements Disclaimer Statement
This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although we believe that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, we can give no assurance that such expectations and assumptions will prove to have been correct. Forward-looking statements are generally identifiable by the use of words like "may," "will," "should," "could," "expect," "anticipate," "estimate," "believe," "intend," or "project" or the negative of these words or other variations on these words or comparable terminology. To the extent that statements in this release are not strictly historical, including without limitation statements as to our ability to improve the outcomes of patients diagnosed with cancer, the potential clinical utility of our proprietary technology platform and the commercial success of our Target Selector™
References:
[1] |
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J Clin. 2017 Jan;67(1):7-30. |
[2] |
Kim TE, Murren JR. Therapy for stage IIIB and stage IV non-small cell lung cancer. Clin Chest Med. 2002 Mar; 23(1):209-224. |
[3] |
Sequist LV, et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol. 2013 Sep 20; 31(27):3327-3334. |
[4] |
Fukuoka M, et al. Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS). J Clin Oncol. 2011 Jul 20; 29(21):2866-2874. |
[5] |
Rosell R, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2012 Mar; 13(3):239-246. |
[6] |
Maemondo M, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med. 2010 Jun 24; 362(25):2380-2388. |
[7] |
Chih-Hsin Yang J et al Afatinib versus cisplatin based chemotherapy for EGFR mutation positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival from two randomized phase 3 trials Lancet Oncology 2015;16 141-151 |
Contact:
LHA Investor Relations
Jcain@lhai.com
310-691-7100
View original content to download multimedia:http://www.prnewswire.com/news-releases/biocept-announces-clinical-validation-and-commercial-launch-of-its-target-selector-multi-gene-liquid-biopsy-panel-for-lung-cancer-300852973.html
SOURCE